After an infection, experts give advice on how to use eye creams correctly.

Published Date: 08 Mar 2023

Following a major outbreak involving the use of tear drops in 13 US states, experts are offering advice on how to protect dry eyes.

Read Full News

Latest News

Endophthalmitis a Risk for Years After Tube Shunt Surgery

The risk for endophthalmitis after glaucoma drainage rises for up to 5 years and is much higher than that for a device-placement surgery for detached retina, a study finds.

Trabeculectomy Often More Cost-Effective Than Tube Shunts

Analysis of data from a randomized trial finds trabeculectomy typically is the better financial bet than tube shunt surgery as a first option to treat glaucoma.

Common Epilepsy Drug Tied to Increased Glaucoma Risk

Use of topiramate is linked to a higher risk for glaucoma than valproate or lamotrigine, especially in women and patients with epilepsy, new research shows.

Worsening Heart-Kidney-Metabolic Health May Threaten Vision

People with worsening cardiovascular-kidney-metabolic syndrome may face an increased risk for developing age-related macular degeneration.

Study Maps Extensive Disease Links Beyond Childhood Eczema

Using millions of NHS records, researchers mapped extensive links between childhood eczema and later inflammatory and eye diseases.

Neoadjuvant Therapy Use Rising Sharply in Cancer Care

The second annual NCDB report reveals a major shift toward preoperative systemic therapy in solid tumors, offering new opportunities for de-escalation, although careful patient selection is needed.

Todays Updates

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Todays Updates

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Latest News

The risk for endophthalmitis after glaucoma drainage rises for up to 5 years and is much higher than that for a device-placement surgery for detached retina, a study finds.

Analysis of data from a randomized trial finds trabeculectomy typically is the better financial bet than tube shunt surgery as a first option to treat glaucoma.

Use of topiramate is linked to a higher risk for glaucoma than valproate or lamotrigine, especially in women and patients with epilepsy, new research shows.

People with worsening cardiovascular-kidney-metabolic syndrome may face an increased risk for developing age-related macular degeneration.

Using millions of NHS records, researchers mapped extensive links between childhood eczema and later inflammatory and eye diseases.

The second annual NCDB report reveals a major shift toward preoperative systemic therapy in solid tumors, offering new opportunities for de-escalation, although careful patient selection is needed.

News All Time

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

Ophthalmology in 2025: Year in Review

Ophthalmology in 2025: Year in Review

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD Srinivas Sadda, MD

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

OCU-410 Gene Therapy Preserves Visual Acuity and Slows GA Lesion Progression, with Jay Chhablani, MD Jay Chhablani, MD

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Intravitreal UBX1325 Shows Efficacy in Diabetic Retinopathy, DME, with Dante Pieramici, MD Dante J. Pieramici, MD

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

Psoriasis Associated with Risk of Age-Related Macular Degeneration Ryan Livingston

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

Correlation Between Diabetes and Risk of Uveitis Confirmed in Recent Study Ryan Livingston

In addition to type 1 and 2 diabetes, diabetic retinopathy substantially increases the risk of developing and worsening uveitis.

Q3 2025 Recap: Ophthalmology News and Updates Ryan Livingston

The Q3 recap for ophthalmology spotlights major FDA decisions and major clinical trial updates in a variety of diseases.

FDA Approves Incision-Free Topical Therapy Epioxa for Keratoconus Ryan Livingston

This approval represents an alternative method for approaching this undertreated disease, shortening recovery while minimizing invasiveness.

Dyslipidemia May Delay Macular Hole Closure After Surgery Ryan Livingston

A recent study highlights correlations between later healing, triglyceride levels, and total cholesterol in patients receiving MH.

FDA Approves Adalimumab-aaty (Yuflyma) Pediatric Indications in Hidradenitis Suppurativa, Uveitis Abigail Brooks, MA

The FDA approved expanded indications for adalimumab-aaty (Yuflyma) and its unbranded version to include the treatment of adolescent HS and pediatric UV.

GLP-1 RAs May Influence Development of Nonexudative AMD in Patients With Obesity Ryan Livingston

Although no direct correlation can be drawn, these findings suggest a possible ocular benefit from GLP-1 RAs compared to other weight loss drugs.

Brolucizumab Outperforms Aflibercept in DME Regardless of Prior Treatment

Brolucizumab Outperforms Aflibercept in DME Regardless of Prior Treatment

Recommended News For You

Sports for girls are frequently abandoned due to uniform issues.

Brain cancer: a Q&A session.

Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

Gene therapy and chemotherapy may be combined in novel ways to treat bone cancer.

Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation

Q&A: How early cancer screening could save Canada nearly half a billion dollars over patients' lifetimes

Decoding calcifications in breast cancer: Towards personalized medicine

Recommended Articles For You

Case Study: Personalized Medicine Based on Genetic Profiling in Oncology 

Enhancing Cancer Care: From Diagnosis Through Survivorship and Beyond 

Genetic Screening: A Game Changer in Cancer Prevention 

Navigating the Unknown: A Guide to Living With Hurthle Cell Thyroid Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Women who miss their first mammogram face higher risk of breast cancer death, study finds

2.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

3.

Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat

4.

High-speed whole-body SPECT tracks tumor evolution to optimize prostate cancer treatment

5.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.

1.

Exosomes in Cancer: A Novel Frontier for Therapy and Biomarker Discovery

2.

Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025

3.

Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia

4.

The Impact of Microadenoma on Hormonal Health

5.

The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

2.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I

4.

Efficient Management of First line ALK-rearranged NSCLC - Part IV

5.

Navigating the Complexities of Ph Negative ALL - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot